Enclosed herewith unaudited Financial Results along with Limited Review Report issued by Statuory Auditor of the Company for the Quarter ended June 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evexia Lifecare's board, meeting on August 14, 2025, approved its Q1 FY26 unaudited results. On a standalone basis, revenue from operations rose to Rs 2,065.80 lakh (vs Rs 1,517.93 lakh in Q4 FY25 and Rs 2,041.87 lakh in Q1 FY25), while net profit jumped to Rs 58.69 lakh from Rs 26.43 lakh a year ago — more than doubling year-on-year. On a consolidated basis, revenue stood at Rs 2,209.32 lakh (vs Rs 2,122.79 lakh in Q1 FY25) and net profit climbed sharply to Rs 63.48 lakh from Rs 24.11 lakh, again a strong YoY rise. Profit before tax improved significantly on both bases, reflecting lower finance costs and tighter expense control. The statutory auditor M. A. Shah & Co. issued an unqualified limited review on both sets of results, with no qualifications or emphasis-of-matter paragraphs.
For shareholders, the filing confirms a solid earnings rebound in Q1 FY26 with profits more than doubling YoY on both standalone and consolidated bases, though revenue growth is modest. The clean auditor review removes near-term governance overhang, which is mildly positive for sentiment; however, the low absolute margin and thin EPS (Rs 0.003 standalone) suggest limited short-term price catalyst beyond improving fundamentals.